Exousia Bio

Exousia Bio is a clinical-stage biotechnology company specializing in exosome-based therapies and diagnostics, primarily for oncology. The company utilizes a proprietary platform to engineer mammalian and plant-derived exosomes for the targeted delivery of nucleic acids, DNA, and other therapeutic molecules. Its lead program is an exosome-based treatment for glioblastoma (GBM), which has received FDA Orphan Drug Designation and is progressing toward Investigational New Drug (IND) trials. Additionally, Exousia Bio is developing a universal cancer screening test based on exosomal NANOG DNA and exploring applications in viral infections and regenerative wellness. The company was formed through a strategic realignment involving Exousia Pro and the acquisition of Exousia AI.